Side-by-side research comparison of Exenatide and Liraglutide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 2 head-to-head studies plus 18 on Exenatide and 479 on Liraglutide.
| Exenatide | Liraglutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist |
| Studies in corpus | 18 | 479 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | rct · 4 meta analysis · 2 other · 5 cohort · 1 review · 1 | rct · 6 cohort · 2 review · 1 meta analysis · 1 in vitro · 2 |
| Studies with explicit sample size | 5 | 3 |
| Head-to-head studies in corpus | 2 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Exenatide and Liraglutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
Fewer than 3 published Exenatide COA records so far — not enough for a meaningful purity aggregate yet. Browse what we have →
We tested 6 Liraglutide batches across 4 manufacturers, 99.6% avg purity.
Studies in our corpus that mention both Exenatide and Liraglutide — the gold-standard direct comparison evidence.
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clinicians and researchers should recognize …
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
Looking for vendor-level purity, endotoxin, and HPLC data on Exenatide or Liraglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.